This call was better than last week. It contained

This call was better than last week. It contained some positive revelations that are of the utmost interest to Cytodyn investors.
The non-binding agreement is a silver lining however, it's "non-binding." That means that neither party is contractually obligated to do anything. It's merely a letter of intent. So I don't think that will not give us the jump we're looking for. It's still positive and newsworthy, but not yet tangible.
I would have liked to see NP open the cc with the fact that Cytodyn is financially current with their vendors, most importantly Samsung Biologics. That's big and was a huge criticism of those who are looking into taking a short position in Cytodyn. It also shows that Cytodyn intends to maintain a fiscally sound relationship with a large manufacturer who will likely be crucial in the future successes of Cytodyn.
Overall, I'm satisfied with the call. I would like to have seen the trials to be a little further along, but the explanation was sufficient and logical.

And I have to point out a pretty funny moment...
Question: "Where is Dr. Patterson?"
Answer: "Probably in his lab working on COVID-19."

Have a pleasant day everyone,